LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Sales of Investments

Cash received from selling or redeeming investments.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments dips below year-ago levels

Q1 FY2026 sales of investments of $49.24M fell 5.5% year over year, behind the +66.5% change in trailing-twelve-month sales of investments. Sequentially, it rose 13.6% from the prior quarter. Over 3 fiscal years it compounded at +6.6% a year.

Context

  • Sales of investments amounted to 1079.0% of revenue in FY2025.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -5.5% toward the trailing-twelve-month pace of +66.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$49.24M+13.6% QoQ
Last fiscal yearDec 2025
$205.96M+134.3% YoY
LTMMar 2026
$203.11M+66.5% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.5%——
1 year+134.3%——
3-year CAGR+6.6%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
205.96M USD
Year-over-year change
+134.3%

Sales of Investments vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +66.5% is the highest of 9, against a peer median of +7.6%.
  • Sales of investments amounts to 967.7% of revenue for LENZ, versus a peer median of 134.5%.
LENZ Competitors
Sales of Investments for LENZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GERNGeron CorporationLTM Mar 2026$399.47M USD+7.9%+8.7%203.7%
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$286M USD+7.3%—288.9%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$203.11M USD+66.5%+6.6%967.7%
TYRATyra Biosciences, Inc.LTM Mar 2026$177M USD+1.3%——
SVRASavara Inc.LTM Mar 2026$176.63M USD+5.2%+8.6%—
RZLTRezolute, Inc.LTM Mar 2026$167.55M USD+45.5%——
PRMEPrime Medicine, Inc.LTM Mar 2026$149.07M USD+10.7%+2.9%3695.3%
ABUSArbutus Biopharma CorporationLTM Mar 2026$125.21M USD-27.8%+40.5%65.4%
GHRSGH Research PLCLTM Mar 2026$63.88M USD+31.7%——
NBTXNanobiotix S.A.FY2025€0 EUR——0.0%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding LENZ) —+7.6%+8.7%134.5%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.76M)(101.05M)(69.97M)(49.77M)(82.13M)
Depreciation & Amortization734K8.35M15K58K(3.12M)
Deferred Income Tax00000
Stock-Based Compensation001.34M6.37M12.55M
Change in Working Capital(2.5M)(7.21M)9.41M(13.09M)3.25M
Accounts Receivables0000(329K)
Inventory0000(4.28M)
Accounts Payables1.83M194K856K(4.28M)(90K)
Other Working Capital(4.32M)(7.4M)8.55M(8.81M)7.95M
Other Non-Cash Items19.67M11.93M(1.18M)(2.95M)279K
Operating Cash Flow(52.85M)(87.98M)(60.38M)(59.39M)(69.17M)
Capital Expenditures(5.74M)(6.59M)(30K)(468K)(827K)
Acquisitions (Net)00000
Purchases of Investments0(405.52M)(52.09M)(241.91M)(280.8M)
Sales of Investments0170.25M22.5M87.9M205.96M
Other Investing Activities00000
Investing Cash Flow(5.74M)(241.86M)(29.62M)(154.48M)(75.67M)
Debt Repayment00000
Common Stock Issued417.16M676K203K79.51M149.75M
Common Stock Repurchased0(79K)000
Dividends Paid00000
Other Financing Activities306K0(2.48M)119.49M0
Financing Cash Flow417.47M597K80.7M199M149.75M
Effect of Forex Changes(1.72M)0000
Net Change in Cash357.16M(329.25M)(9.3M)(14.87M)4.91M
Free Cash Flow(58.59M)(94.57M)(60.41M)(59.86M)(70M)

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.